🚀 Today we’re announcing our integration of Mobilise-D's digital mobility outcomes into the Empatica Health Monitoring Platform, providing 25 new validated measures for COPD, Parkinson’s disease, multiple sclerosis, hip fracture recovery, and congestive heart failure. Mobilise-D is a consortium funded under the EU Innovative Medicines Initiative and EFPIA partners, to develop a novel method to accurately and reliability assess change in one’s mobility in the real-world environment using digital technologies. “We are proud to be the first company to implement the Mobilise-D consortium’s groundbreaking development and validation work”, said our CTO and Co-Founder, Simone Tognetti. “The demand for high-quality, purpose-specific measures is immense, and Empatica is ready to support the dissemination of the consortium’s innovative work within the industry.” Read our press release ➡️ https://lnkd.in/dNYhNWV5 #WearableTechnology #DigitalBiomarkers
Empatica
Biotechnology Research
Boston, Massachusetts 32,873 followers
Medical wearables and AI that empower thousands of patients, clinicians and researchers with real-time human insight.
About us
Empatica is an affective computing company, focused on human data analytics. We develop groundbreaking wearable devices with medical quality sensing. Our technology comprises a set of wristband, software running on smartphone and desktop computing, plus real time syncing with a cloud computing service.
- Website
-
https://www.empatica.com
External link for Empatica
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2011
- Specialties
- Affective Computing, Software Development, Hardware Development, and Wearable Computing
Locations
-
Primary
45 Bromfield St
901
Boston, Massachusetts 02108, US
-
Via Stendhal, 36
Milano, MI 20144, IT
Employees at Empatica
Updates
-
We’re proud to have partnered with top researchers and hospitals to publish 12,000+ publications using Empatica’s tech. ➡️ Discover a selection of these studies on our new publications page: https://lnkd.in/di2YP-Ne
-
-
🎉 Applications for Empatica’s Engineering Graduate Program are now open! Each year, 2 graduate students are given the opportunity to dive into the intricacies of digital healthcare, solving real problems while joining a team of young, friendly, and international people eager to make a difference. 📆 Applications close on July 31st 2024. Apply here: https://lnkd.in/drES5mpm #ApplyNow #ApplyToday #LifeAtEmpatica #WearableTechnology #Engineering
-
-
Wishing all of our customers and clients in the USA a very happy Independence Day 🇺🇸 #HappyFourthofJuly #July4 #IndependenceDay
-
-
The integration of third party algorithms in a pre-existing solution, such as the Empatica Health Monitoring Platform, provides a range of benefits for #DataScientists. Benefits include: 1️⃣ No need to worry about the development of dedicated hardware and compatible software 2️⃣ More time to focus your energies on developing new endpoints 3️⃣ See your algorithms commercialized and implemented in large-scale initiatives Discover more on Empatica’s 200+ #DigitalBiomarker offering, the largest range in research from a single wearable: https://lnkd.in/dcS3wA9j
-
-
Last week, our Clinical Science Program Manager, Jessie Lever Taylor, showcased a poster at the 'Unlocking Human Potential' event. This event was hosted by Mass General Brigham, the University of Massachusetts Lowell, the National Defense Industrial Association - (NDIA), and MassChallenge.
-
-
🚀 #WeAreHiring a Software QA Engineer in Milan, Italy! In this role, you’ll design and execute tests and ensure flawless feature implementation. The ideal candidates will have 3+ years of experience in Manual Software Testing, as well as IT and mobile testing experience on iOS and Android. ➡️ #ApplyToday before you miss out: https://lnkd.in/dwKjpmuM #Vacancy #LifeAtEmpatica
-
-
🚀 In case you missed it, we recently partnered with Mobilise-D , to integrate their digital mobility outcomes into the Empatica Health Monitoring Platform. Our platform now provides 25 new validated measures for COPD, Parkinson’s disease, multiple sclerosis, hip fracture recovery, and congestive heart failure. Read our blog to find out more: https://lnkd.in/d53PfQRZ #DigitalBiomarkers
-
-
Yesterday our CEO and Co-founder, Matteo Lai, took part in the ‘Digital Biomarkers in Cardiovascular, Metabolism, Immunology and Ophthalmology’ panel discussion at PanAgora Pharma’s #DigitalBiomarkersSummit.
-